HIV-1 gp41 Subtype-b&c
Escherichia Coli.
Sterile Filtered clear solution.
Protein is >90% pure as determined by 10% PAGE (coomassie staining).
Description
Recombinant mosaic HIV-1 gp41 Subtype-c & subtype-b produced in E. coli having a Mw of 38kDa.
Recombinant HIV-1 gp41 Subtype-c and subtype-b is fused to GST tag at its N-terminus and purified by proprietary chromatographic technique.
Product Specs
The human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. It weakens the immune system, making individuals susceptible to opportunistic infections. HIV primarily targets essential immune cells like helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells, leading to a decline in CD4+ T cells. This decline occurs through: direct viral killing of infected cells; increased cell death (apoptosis) in infected cells; and destruction of infected CD4+ T cells by CD8 cytotoxic lymphocytes. When CD4+ T cell counts drop significantly, cell-mediated immunity is compromised, increasing vulnerability to opportunistic infections. HIV is classified under the Lentivirus genus within the Retroviridae family. Lentiviruses share common characteristics and biological features, often causing prolonged illnesses with extended incubation periods in various species. In lateral flow assays, the HIV-1 gp41 Subtype-c protein is commonly used to detect antibodies specific to HIV-1 infection. It serves as a capture agent on the test membrane to bind with these antibodies.
This product consists of a recombinant mosaic of HIV-1 gp41 Subtype-c and subtype-b, produced in E. coli, with a molecular weight of 38kDa. It features a GST tag fused to its N-terminus and has been purified using a proprietary chromatographic method.
A clear, sterile-filtered solution.
The HIV-1 gp41 Subtype-c solution is formulated with PBS and 25mM K2CO3.
For short-term storage (2-4 weeks), the solution should be kept at 4°C. For longer storage, freeze the solution at -20°C. Adding a carrier protein such as 0.1% HSA or BSA is recommended for long-term storage. Avoid repeatedly freezing and thawing the product.
The protein purity is greater than 90%, as determined by 10% PAGE (coomassie staining).
This product is suitable for use in ELISA and lateral flow assays.
Escherichia Coli.
Product Science Overview
HIV-1 (Human Immunodeficiency Virus type 1) is the primary cause of AIDS (Acquired Immunodeficiency Syndrome). The virus has several subtypes, with Subtype B and Subtype C being among the most prevalent. The HIV-1 envelope glycoprotein (Env) consists of two subunits: gp120 and gp41. The gp41 subunit plays a crucial role in the fusion of the viral membrane with the host cell membrane, a key step in viral entry and infection.
The gp41 protein is a transmembrane glycoprotein that facilitates the fusion of the HIV-1 virus with the host cell. It undergoes a series of conformational changes to mediate this process. The gp41 subunit is composed of several regions, including the fusion peptide, heptad repeats (HR1 and HR2), and the membrane-proximal external region (MPER). These regions are critical for the protein’s function in viral entry .
Recombinant gp41 proteins are engineered versions of the gp41 subunit, designed to study its structure and function or to develop therapeutic interventions. These recombinant proteins can be produced in various systems, such as bacteria, yeast, or mammalian cells. They are often used in research to understand the mechanisms of viral entry and to develop vaccines or inhibitors that target gp41.
Subtype B and Subtype C are two of the most common subtypes of HIV-1. Subtype B is predominantly found in North America and Europe, while Subtype C is more prevalent in sub-Saharan Africa and parts of Asia. These subtypes have genetic variations that can affect the structure and function of gp41, making it important to study them separately.
Recombinant gp41 proteins from Subtype B and Subtype C are used in various applications, including:
- Vaccine Development: Researchers use recombinant gp41 to develop vaccines that elicit an immune response against the virus.
- Therapeutic Research: Recombinant gp41 is used to screen for inhibitors that can block the fusion process and prevent viral entry.
- Structural Studies: By studying the structure of recombinant gp41, scientists can gain insights into the conformational changes that occur during viral fusion .
